We now have a timeline after the 10Q for the third quarter of 2011, in which we have learned that the China trials are starting in 2012 for all three Apoptone, Triolex and HE2000. It is in my opinion a favourable news item. In addition the Q3 net loss is a small 0.8 million USD and the cash on hand and shareholder's equity are ahead (better) as compared to my internal (yes I tend to analyse) estimations. This Company is the cheapest in the world, it is an accumulate. In addition I learned from the 10Q that 10,000 (ten thousand) pages of information were being provided by Harbor BioSciences to Sinopharm. This is my favourite stock, together with Arthur (traded on the Euronext Brussels Exchange at 1.15 euro with 6.70 euro bookvalue).